Ideal Cures releases new film coating materials
Indian excipient manufacturing company, Ideal Cures, has launched a new range of film coating materials under Instacoat E Series.
The portfolio of coating products in the Instacoat brand include, Instacoat EHP 250, Instacoat EMB, Instacoat EEN and Instacoat EHA.
Instacoat EHP 250 is a single polymer (PVA- Poly-Vinyl Alcohol) based fully aqueous coating system.
EMB acts as an aqueous and fast coating system for specifically highly moisture sensitive drugs, as it has moisture barrier properties.
EEN is optimized enteric coating achieved with minimum weight gain for the enteric or delayed release products.
EHA is a high adhesion, immediate release HPMC based film coating system.
The disintegration time and dissolution rates of the tablets products are not affected with film coatings using EHP 250 and EMB, the company said.
Related Insight
Suppliers Directory
Chemetall - Tools for Organic Synthesis
Chemetall is a global company committed to specialty chemistry. The Lithium Division of Chemetall is the world’s leading supplier of Lithium compounds. Following to our expertise in this field of chemistry we also supply other organometallic compounds such as Grignard reagents, Amides and Alkoxides.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Lomapharm - Your Competent Partner for Solid and Liquid Pharmaceuticals
Lomapharm®: Pharmaceutical competence with a long tradition.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Hovione - API Development
When you really care about quality and performance, Hovione is your API
Hovione is an international company with over 50 years’ experience in API development and compliant manufacture. With FDA inspected sites in the US, China, Ireland, and Portugal the company focuses on the most demanding customers, in the most regulated markets. The company offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Fine & Speciality Chemicals Intelligence
SynBiosys™ Injectable Implants
Published by InnoCore Technologies BV
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Building Blocks For Click Chemistry
Published by IRIS Biotech
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.